PMID- 30720082
OWN - NLM
STAT- MEDLINE
DCOM- 20190730
LR  - 20211204
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 19
IP  - 4
DP  - 2019 Apr
TI  - Knockdown of ARK5 expression suppresses invasion of ovarian cancer cells.
PG  - 2927-2934
LID - 10.3892/mmr.2019.9901 [doi]
AB  - The aim of the current study was to investigate the effects and the molecular 
      mechanisms of ARK5 in ovarian cancer cell invasion. The plasmid 
      pGCsilencerU6/GFP/Neo‑RNAi‑ARK5 and the control vector with a scramble sequence 
      were transfected into SKOV3 cells to establish ARK5‑deficient SKOV3 cells 
      (siARK5/SKOV3) and a control cell line (Scr/SKOV3), respectively. Reverse 
      transcription‑polymerase chain reaction (RT‑PCR) and Western blot analysis were 
      used to determine the mRNA and protein expression levels of ARK5. Migration and 
      invasion abilities of SKOV3 cells were determined in chemotaxis and invasion 
      assays, respectively. The epidermal growth factor‑1 (EGF‑1)‑induced expression of 
      matrix metallopeptidase (MMP)‑2 and MMP‑9, epithelial‑mesenchymal transition 
      (EMT) and phosphorylation of mechanistic target of rapamycin kinase (mTOR) in 
      siARK5/SKOV3 and Scr/SKOV3 cells were detected by western blot. RT‑PCR and 
      western blot analyses demonstrated that the expression of ARK5 was significantly 
      downregulated in siARK5/SKOV3 cells at the mRNA and protein levels (P<0.01). The 
      migration and invasion abilities of siARK5/SKOV3 cells were markedly decreased 
      compared with Scr/SKOV3 cells (P<0.01). In addition, the results demonstrated 
      that EGF‑1‑induced expression of MMP‑2 and MMP‑9, EMT and phosphorylation of mTOR 
      were suppressed in siARK5/SKOV3 cells as compared with Scr/SKOV3 cells (P<0.01). 
      The current study demonstrated that ARK5 is a critical factor involved in SKOV3 
      cell invasion and ARK5 increases invasive potential by promoting EMT and 
      activating the Akt‑mTOR‑MMPs pathway.
FAU - Wang, Shuxiao
AU  - Wang S
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Li, Shuwei
AU  - Li S
AD  - Department of Physics, Weifang Medical University, Weifang, Shandong 261053, P.R. 
      China.
FAU - Wang, Hui
AU  - Wang H
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Gynecology, Zhenjiang Maternity and Child Health Hospital, 
      Zhenjiang, Jiangsu 212001, P.R. China.
FAU - Gao, Yuxue
AU  - Gao Y
AD  - Department of Pathology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Wang, Xuejian
AU  - Wang X
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Fang, Chunyan
AU  - Fang C
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Zhang, Baogang
AU  - Zhang B
AD  - Department of Pathology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Sun, Xiuning
AU  - Sun X
AD  - Department of Microbiology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Li, Ruifang
AU  - Li R
AD  - Department of Microbiology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Shi, Weiwei
AU  - Shi W
AD  - Department of Chemistry, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Chen, Meiling
AU  - Chen M
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Shi, Lihong
AU  - Shi L
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20190128
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Repressor Proteins)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.- (NUAK1 protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation
MH  - Female
MH  - Gene Knockdown Techniques
MH  - *Gene Silencing
MH  - Humans
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Neoplasm Invasiveness/genetics
MH  - Ovarian Neoplasms/*genetics/metabolism/pathology
MH  - Protein Kinases/*genetics/metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Repressor Proteins/*genetics/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
EDAT- 2019/02/06 06:00
MHDA- 2019/07/31 06:00
CRDT- 2019/02/06 06:00
PHST- 2018/03/04 00:00 [received]
PHST- 2018/12/06 00:00 [accepted]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2019/07/31 06:00 [medline]
PHST- 2019/02/06 06:00 [entrez]
AID - 10.3892/mmr.2019.9901 [doi]
PST - ppublish
SO  - Mol Med Rep. 2019 Apr;19(4):2927-2934. doi: 10.3892/mmr.2019.9901. Epub 2019 Jan 
      28.